Loading
A phase 3 trial of H101 oncolytic adenovirus in Hepatocellular carcinoma, run by Sun Yat-sen University, with a status the registry has not verified recently.
HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B is a phase 3 interventional study registered as NCT03780049 by Sun Yat-sen University, with 304 participants planned, started 2018-10-01 and due to reach its primary completion in 2023-10-01. Interventions recorded: HAIC of FOLFOX, H101, Placebos. Conditions recorded: Hepatocellular Carcinoma.
Linked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares H101 oncolytic adenovirus and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares H101 oncolytic adenovirus and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/